MX2007015474A - Proteasas para uso farmaceutico. - Google Patents

Proteasas para uso farmaceutico.

Info

Publication number
MX2007015474A
MX2007015474A MX2007015474A MX2007015474A MX2007015474A MX 2007015474 A MX2007015474 A MX 2007015474A MX 2007015474 A MX2007015474 A MX 2007015474A MX 2007015474 A MX2007015474 A MX 2007015474A MX 2007015474 A MX2007015474 A MX 2007015474A
Authority
MX
Mexico
Prior art keywords
pharmaceutical use
proteases
diabetes type
pancreatitis
pei
Prior art date
Application number
MX2007015474A
Other languages
English (en)
Inventor
Allan Svendsen
Peter Colin Gregory
Claus Crone Fuglsang
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of MX2007015474A publication Critical patent/MX2007015474A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invencion se refiere al uso farmaceutico de las proteasas relacionadas con los aminoacidos 1-274 de la SEC ID NO 2, a la serina proteasa derivada de Bacillus licheniformis, la cual tambien esta designada como subtilisina Calsberg, opcionalmente en combinacion con una lipasa y/o una amilasa. Los ejemplos de las indicaciones medicas son: el tratamiento de los trastornos digestivos, insuficiencia pancreatica exocrina (PEI), pancreatitis, fibrosis quistica, diabetes del tipo I, y/o diabetes del tipo II.
MX2007015474A 2005-06-24 2006-06-16 Proteasas para uso farmaceutico. MX2007015474A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500930 2005-06-24
DKPA200501643 2005-11-23
PCT/DK2006/000353 WO2006136160A2 (en) 2005-06-24 2006-06-16 Proteases for pharmaceutical use

Publications (1)

Publication Number Publication Date
MX2007015474A true MX2007015474A (es) 2008-04-22

Family

ID=36808352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015474A MX2007015474A (es) 2005-06-24 2006-06-16 Proteasas para uso farmaceutico.

Country Status (13)

Country Link
US (3) US20080317726A1 (es)
EP (1) EP1896058A2 (es)
JP (1) JP2008546395A (es)
KR (1) KR20080017039A (es)
AU (1) AU2006261443A1 (es)
BR (1) BRPI0611936A2 (es)
CA (1) CA2612806A1 (es)
IL (1) IL187510A0 (es)
MX (1) MX2007015474A (es)
NO (1) NO20080438L (es)
NZ (1) NZ563777A (es)
RU (1) RU2420578C2 (es)
WO (1) WO2006136160A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563737A (en) * 2005-06-24 2010-08-27 Novozymes As Amylases derived from Bacillus stearothermophilus optionally in combination with proteases and/or lipases for pharmaceutical use
CA3081308C (en) 2006-12-21 2024-02-20 Novozymes A/S Lipase variants for pharmaceutical use
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
US20110171294A1 (en) * 2008-09-30 2011-07-14 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US8262912B1 (en) * 2009-06-05 2012-09-11 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
US9056265B2 (en) 2009-06-05 2015-06-16 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
WO2014130007A1 (en) * 2013-02-19 2014-08-28 Deerland Enzymes, Inc. Proteolytic compositions for rapidly and extensively degrading protein supplements
WO2017080511A1 (en) * 2015-11-12 2017-05-18 Novozymes A/S Agitation, aeration and /or fermentation processes with reduced foam
MX2020002177A (es) * 2017-09-01 2020-07-14 Novozymes As Aditivos para pienso para animales que comprenden un polipéptido que tiene actividad proteasa y usos de estos.
WO2022256691A1 (en) * 2021-06-04 2022-12-08 Amyris, Inc. Methods of purifying cannabinoid
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US6413512B1 (en) * 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
HUP0200556A3 (en) * 1999-03-17 2006-06-28 Solvay Pharm Gmbh Medicament for treating diabetes
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
CN100489094C (zh) * 2001-03-23 2009-05-20 金克克国际有限公司 具有改变的免疫原性反应的蛋白质及制备和使用该蛋白质的方法
CA2501645A1 (en) * 2002-10-10 2004-04-22 Diversa Corporation Proteases, nucleic acids encoding them and methods for making and using them
DE10260903A1 (de) * 2002-12-20 2004-07-08 Henkel Kgaa Neue Perhydrolasen
WO2004078773A1 (en) * 2003-03-03 2004-09-16 Oregon Health And Science University Stabilizing proteins for use in personal care, cosmetic, and pharmaceutical products

Also Published As

Publication number Publication date
US20100135978A1 (en) 2010-06-03
KR20080017039A (ko) 2008-02-25
JP2008546395A (ja) 2008-12-25
AU2006261443A1 (en) 2006-12-28
NO20080438L (no) 2008-02-15
US20080317726A1 (en) 2008-12-25
EP1896058A2 (en) 2008-03-12
RU2420578C2 (ru) 2011-06-10
NZ563777A (en) 2010-08-27
WO2006136160A3 (en) 2007-09-20
BRPI0611936A2 (pt) 2011-02-22
RU2008102738A (ru) 2009-07-27
CA2612806A1 (en) 2006-12-28
US20110110910A1 (en) 2011-05-12
WO2006136160A2 (en) 2006-12-28
IL187510A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
MX2007015474A (es) Proteasas para uso farmaceutico.
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
TW200738256A (en) Lipases for pharmaceutical use
NO20080439L (no) Amylaser til farmasoytisk anvendelse
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
Araujo et al. Peptidase specificity characterization of C-and N-terminal catalytic sites of angiotensin I-converting enzyme
NZ596269A (en) Protease screening methods and proteases identified thereby
Banbula et al. Prolyl tripeptidyl peptidase from Porphyromonas gingivalis: a novel enzyme with possible pathological implications for the development of periodontitis
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
WO2005111203A3 (en) MUTANT α ΑMYLASES
MX2009012682A (es) Variantes mejoradas de la alfa-amilasa de bacillus licheniformis.
JP2008521906A5 (es)
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
MX2010004371A (es) Proteasa de streptomyces.
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
NZ508460A (en) Production of hydrolysate seasoning
Bersanetti et al. Characterization of arazyme, an exocellular metalloprotease isolated from Serratia proteamaculans culture medium
Kageyama Role of S ‘1 loop residues in the substrate specificities of pepsin A and chymosin
Adamitsch et al. Proteolytic activity of a yeast cell wall lytic Arthrobacter species
EP1474509A4 (en) AGGRECANASE 1 AND 2 PEPTIDE SUBSTRATES AND METHOD
Donlon Subtilisin
Skidgel Characterization of the metabolism of substance P and neurotensin by human angiotensin I converting enzyme and" enkephalinase".
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
Bontemps et al. Inhibitory feature of the proprotein convertases prosegments

Legal Events

Date Code Title Description
FA Abandonment or withdrawal